This is my original abstract: We present a patient who experienced a diffuse inflammatory, treatment-refractory reaction to the biostimulatory soft-tissue filler calcium hydroxylapatite with integral lidocaine due to undiagnosed Hashimoto’s thyroiditis that resolved rapidly with exogenous thyroid hormone replacement.

I need you to make a longer, more through abstract in comparison to what I already have. This will be presented in a medical journal. Everything below is the rest of the case report paper

Introduction: Calcium hydroxylapatite (CaHA) with or without integral 0.3% lidocaine hydrochloride (Radiesse and Radiesse+, respectively, Merz North America, Inc., Raleigh, NC) is a biostimulatory soft tissue filler approved by the American Food and Drug Administration in 2006 for the correction of moderate-to-severe wrinkles and folds of the face [1]. There have been prior reports of inflammatory complications associated with CaHA, including nodules and alopecia secondary to foreign-body reactions [2, 3]. We present here a patient who experienced a diffuse inflammatory reaction to CaHA with integral lidocaine due to undiagnosed Hashimoto’s thyroiditis. 

Case Presentation: A healthy 43-year-old woman (Figure 1A) was treated with 1 syringe (1.5 mL) of CaHA with integral lidocaine. Subdermal injection was performed into the temples, malar and buccal cheeks, nasolabial folds, and marionette lines using a 25G blunt-tipped cannula. The patient had previously been treated with CaHA, poly-L-lactic acid, and hyaluronic acid fillers in these same facial locations without complications. Three weeks post-injection, the patient complained of progressive swelling and firmness of her cheeks of 3 days duration. Physical examination revealed diffuse induration and warmth in treated areas (Figure 1B), without evidence of pain, tenderness, or intense erythema that would indicate cellulitis. The patient denied fever or recent illnesses. She was started on minocycline 100 mg capsules po BID for 2 weeks and prednisone 10 mg po qdaily for 3 days for a suspected foreign body reaction. Two weeks later, the patient reported no improvement, despite completing the course of minocycline and prednisone. On examination, there was persistent painless, nonfluctuant subcutaneous edema, induration, and warmth that was greatest in the bilateral malar and buccal cheeks, but also present in the nasolabial folds, temple, and marionette line areas. The patient was prescribed furosemide 20 mg po qdaily for 2 days to help reduce the edema and doxycycline 75 mg po qdaily mouth daily for 1 month as a continued anti-inflammatory, but neither led to significant improvement. However, the patient was shortly later diagnosed with Hashimoto’s thyroiditis by her primary care physician and started on levothyroxine po qdaily (titrated to a daily dose of 100 mcg), leading to complete resolution of her signs and symptoms within 7-10 days of starting the exogenous thyroid hormone.

Discussion:CaHA is a well-tolerated, biostimulatory, and biodegradable soft tissue filler. Adverse events from CaHA (e.g., erythema, edema, pain, tenderness, induration, and ecchymosis) are primarily mild, injection-related, and transient, resolving within hours to days following treatment [1]. Subacute-onset (2 weeks to 1 year) or late-onset (>1 year) filler-associated nodules can be either noninflammatory or inflammatory [4]. The former are asymptomatic and may be due to overcorrection, overly superficial placement, or product migration. Inflammatory nodules, on the other hand, can exhibit pain, tenderness, warmth, erythema, edema, and induration. While localized painful lesions can develop due to poor aseptic technique (subacute) or biofilm formation (late), diffuse lower-grade inflammation may be of infectious or autoimmune etiology [4]. Given the mild diffuse inflammatory reaction to CaHA in our patient, an autoimmune-mediated foreign-body granulomatous reaction, caused by macrophage activation and subsequent T-cell response, is the likely explanation. Not surprisingly, it is thought that defects in regulatory T-cells and increased activation of follicular helper T-cells play a major role in the pathogenesis of Hashimoto’s thyroiditis [5].

Conclusions: Due to the potential inflammatory complications of CaHA, its use should be avoided in patients with uncontrolled autoimmune disease. Acute onset autoimmune disease should likewise be considered in patients who develop prolonged inflammatory edema and induration within several weeks of CaHA injection. As seen in this case, inflammatory reactions to CaHA associated with autoimmune hypothyroidism may rapidly respond to exogenous thyroid hormone replacement therapy.